Skip to main content

Table 1 Patient demographics and disease characteristics

From: Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis

  Sarilumab SC 200 mg q2w (n = 184) Adalimumab SC 40 mg q2w (n = 185)
Demographics
 Age, years, mean ± SD 50.9 ± 12.6 53.6 ± 11.9
 Female sex, n (%) 157 (85.3) 150 (81.1)
 Race, white, n (%) 171 (92.9) 164 (88.6)
 Weight, kg, mean ± SD 72.3 ± 16.5 71.8 ± 17.8
 BMI, kg/m2, mean ± SD 27.1 ± 5.6 27.3 ± 6.5
Geographic region, n (%)a
 1 61 (33.2) 62 (33.5)
 2 36 (19.6) 35 (18.9)
 3 87 (47.3) 88 (47.6)
Disease and treatment history
 Duration of RA, years, mean ± SD 8.1 ± 8.1 6.6 ± 7.8
 Rheumatoid factor-positive, n (%)b 119 (66.9) 116 (64.8)
 Anti-CCP autoantibody-positive, n (%)c 134 (75.3) 138 (76.7)
Number of prior csDMARDs, n (%)
 0 0 0
 1 83 (45.1) 88 (47.6)
 2 57 (31.0) 58 (31.4)
  ≥ 3 44 (23.9) 39 (21.1)
Prior csDMARDs other than MTX, n (%)d   
 Sulfasalazine 59 (32.1) 44 (23.8)
 Leflunomide 42 (22.8) 45 (24.3)
 Hydroxychloroquine 41 (22.3) 43 (23.2)
Prior csDMARDs in combination with MTX, n (%) 35 (19.0) 44 (23.8)
Reason for stopping MTX, n (%)
 Inadequate responder 97 (52.7) 103 (55.7)
 Intolerant 87 (47.3) 81 (43.8)
 Inappropriate for continued treatment 0 1 (0.5)
Concomitant oral corticosteroids, n (%) 98 (53.3) 104 (56.2)
Disease activity, mean ± SD
 DAS28-ESRe 6.8 ± 0.8 6.8 ± 0.8
 DAS28-CRPe 6.0 ± 0.9 6.0 ± 0.9
 Swollen joint count (66 assessed)e 18.6 ± 10.7 17.5 ± 10.3
 Tender joint count (68 assessed)e 28.0 ± 13.2 26.7 ± 13.6
 CDAIe 43.6 ± 12.1 42.4 ± 12.0
 ESR, mm/he 46.5 ± 21.8 47.5 ± 23.2
 CRP, mg/Le 17.4 ± 21.3 24.1 ± 31.0
  1. Abbreviations: BMI Body mass index, CCP Cyclic citrullinated peptide, CDAI Clinical Disease Activity Index, CRP, C-reactive protein, csDMARD Conventional synthetic disease-modifying antirheumatic drug, DAS28 28-joint Disease Activity Score, ESR Erythrocyte sedimentation rate, MTX Methotrexate, q2w Every 2 weeks, RA Rheumatoid arthritis, SC Subcutaneous
  2. aRegion 1 (Western countries): Czech Republic, Germany, Hungary, Israel, Spain, United States. Region 2 (South America): Chile, Peru. Region 3 (rest of the world): Poland, South Africa, South Korea, Romania, Russia, Ukraine
  3. bAdalimumab group, n = 179; sarilumab group, n = 178
  4. cAdalimumab group, n = 180; sarilumab group, n = 178
  5. dIncluded if used in > 5% of the population
  6. eHigher numbers represent more severe disease